Stephen K. Brannan - Jan 9, 2023 Form 4 Insider Report for Karuna Therapeutics, Inc. (KRTX)

Role: Chief Medical Officer
Signature: /s/ Troy Ignelzi, Attorney-in-Fact
Stock symbol: KRTX
Transactions as of: Jan 9, 2023
Transactions value $: -$954,029
Form type: 4
Date filed: 1/9/2023, 04:27 PM
Previous filing: Dec 12, 2022
Next filing: Feb 13, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRTX	Common Stock	Options Exercise	$8.32K	+1.53K	+10.18%	$5.45^*	16.5K	Jan 9, 2023	Direct
transaction	KRTX	Common Stock	Sale	-$302K	-1.53K	-9.24%	$197.52	15K	Jan 9, 2023	Direct	F1
transaction	KRTX	Common Stock	Options Exercise	$25.2K	+3.47K	+23.15%	$7.27^*	18.5K	Jan 9, 2023	Direct
transaction	KRTX	Common Stock	Sale	-$686K	-3.47K	-18.8%	$197.52	15K	Jan 9, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-1.53K	-4.22%	$0.00	34.7K	Jan 9, 2023	Common Stock	1.53K	$5.45	Direct	F2
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-3.47K	-100%	$0.00^*	0	Jan 9, 2023	Common Stock	3.47K	$7.27	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2022.
F2	This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter.
F3	This option vested as to 12.5% of the shares underlying the option award on each six month anniversary following the vesting commencement date of August 8, 2018.